News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
852,943 Results
Type
Article (86886)
Company Profile (704)
Press Release (765352)
Multimedia
Podcasts (147)
Webinars (19)
Section
Business (232822)
Career Advice (4133)
Deals (39763)
Drug Delivery (129)
Drug Development (91111)
Employer Resources (198)
FDA (18188)
Job Trends (17364)
News (396855)
Policy (39825)
Tag
Academia (3002)
Academic (2)
Accelerated approval (12)
Adcomms (32)
Allergies (106)
Alliances (56975)
ALS (119)
Alzheimer's disease (1571)
Antibody-drug conjugate (ADC) (188)
Approvals (18141)
Artificial intelligence (401)
Autoimmune disease (37)
Automation (19)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (136)
Biotechnology (482)
Bladder cancer (100)
Brain cancer (41)
Breast cancer (392)
Cancer (3097)
Cardiovascular disease (249)
Career advice (3541)
Career pathing (34)
CAR-T (209)
CDC (41)
Cell therapy (576)
Cervical cancer (24)
Clinical research (74321)
Collaboration (1111)
Company closure (3)
Compensation (711)
Complete response letters (34)
COVID-19 (2905)
CRISPR (67)
C-suite (358)
Cystic fibrosis (121)
Data (3093)
Decentralized trials (2)
Denatured (51)
Depression (77)
Diabetes (380)
Diagnostics (6980)
Digital health (26)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (183)
Drug pricing (152)
Drug shortages (36)
Duchenne muscular dystrophy (134)
Earnings (97523)
Editorial (48)
Employer branding (25)
Employer resources (169)
Events (131474)
Executive appointments (909)
FDA (19931)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1019)
Gene editing (147)
Generative AI (40)
Gene therapy (438)
GLP-1 (937)
Government (5263)
Grass and pollen (6)
Guidances (181)
Healthcare (20917)
HIV (45)
Huntington's disease (32)
IgA nephropathy (44)
Immunology and inflammation (185)
Immuno-oncology (11)
Indications (40)
Infectious disease (3102)
Inflammatory bowel disease (165)
Inflation Reduction Act (13)
Influenza (71)
Intellectual property (125)
Interviews (813)
IPO (17906)
IRA (55)
Job creations (5194)
Job search strategy (2863)
Kidney cancer (15)
Labor market (56)
Layoffs (592)
Leadership (26)
Legal (10137)
Liver cancer (85)
Longevity (12)
Lung cancer (433)
Lymphoma (216)
Machine learning (11)
Management (65)
Manufacturing (446)
MASH (99)
Medical device (14730)
Medtech (14735)
Mergers & acquisitions (22585)
Metabolic disorders (968)
Multiple sclerosis (104)
NASH (23)
Neurodegenerative disease (142)
Neuropsychiatric disorders (42)
Neuroscience (2328)
NextGen: Class of 2025 (7687)
Non-profit (5090)
Now hiring (48)
Obesity (496)
Opinion (291)
Ovarian cancer (104)
Pain (121)
Pancreatic cancer (125)
Parkinson's disease (201)
Partnered (25)
Patents (320)
Patient recruitment (173)
Peanut (55)
People (65726)
Pharmaceutical (143)
Pharmacy benefit managers (25)
Phase I (22938)
Phase II (32270)
Phase III (24299)
Pipeline (1703)
Policy (243)
Postmarket research (3552)
Preclinical (10359)
Press Release (72)
Prostate cancer (150)
Psychedelics (46)
Radiopharmaceuticals (279)
Rare diseases (527)
Real estate (7402)
Recruiting (76)
Regulatory (27183)
Reports (61)
Research institute (2666)
Resumes & cover letters (650)
Rett syndrome (10)
RNA editing (10)
RSV (58)
Schizophrenia (98)
Series A (173)
Series B (118)
Service/supplier (30)
Sickle cell disease (67)
Special edition (22)
Spinal muscular atrophy (168)
Sponsored (37)
Startups (4305)
State (2)
Stomach cancer (17)
Supply chain (84)
Tariffs (65)
The Weekly (94)
Vaccines (919)
Venture capital (58)
Weight loss (332)
Women's health (52)
Worklife (20)
Date
Today (90)
Last 7 days (404)
Last 30 days (2033)
Last 365 days (34034)
2025 (18482)
2024 (38139)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1273)
Alabama (70)
Alaska (7)
Arizona (281)
Arkansas (14)
Asia (50540)
Australia (8878)
California (7799)
Canada (2417)
China (727)
Colorado (340)
Connecticut (348)
Delaware (205)
Europe (115947)
Florida (1157)
Georgia (264)
Hawaii (2)
Idaho (66)
Illinois (742)
India (33)
Indiana (386)
Iowa (18)
Japan (239)
Kansas (116)
Kentucky (33)
Louisiana (18)
Maine (73)
Maryland (1105)
Massachusetts (5967)
Michigan (276)
Minnesota (485)
Mississippi (3)
Missouri (101)
Montana (32)
Nebraska (26)
Nevada (83)
New Hampshire (73)
New Jersey (2192)
New Mexico (31)
New York (2187)
North Carolina (1247)
North Dakota (10)
Northern California (3361)
Ohio (252)
Oklahoma (17)
Oregon (48)
Pennsylvania (1663)
Puerto Rico (18)
Rhode Island (39)
South America (1654)
South Carolina (36)
South Dakota (1)
Southern California (2887)
Tennessee (129)
Texas (1197)
United States (29453)
Utah (231)
Virginia (213)
Washington D.C. (80)
Washington State (690)
West Virginia (4)
Wisconsin (86)
There are 852,943 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IN PARTNERSHIP WITH EVOTEC
Webinar: Pharma Industry in Crisis
With venture funding tightening in the post-COVID landscape, efficiency has become more critical than ever. In this interactive webinar industry experts explored actionable strategies for maintaining quality under financial pressure. Watch now.
July 16, 2025
·
1 min read
·
BioSpace Insights
Rare diseases
AstraZeneca’s Amyloidosis Asset Stumbles in Late-Stage Trials
The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an unspecified patient subgroup.
July 16, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Clinical Oncology Next Generation Sequencing Market Size to Reach USD 2,129.82 Million By 2034
July 16, 2025
·
1 min read
Press Releases
Advanced Therapies in Biopharmaceutical Medicine Market Growth Accelerates with AI, Oncology Demand and RMAT Approvals in 2025
July 16, 2025
·
1 min read
Earnings
J&J Targets $50B Oncology Sales By 2030: Updated
Johnson & Johnson’s $23.7 billion in second-quarter earnings, driven by cancer and neuroscience drugs, exceeded analyst expectations, while CEO Joaquin Duato set a target of $50 billion in oncology sales by 2030.
July 16, 2025
·
2 min read
·
Nick Paul Taylor
Antibody-drug conjugate
GSK’s Blenrep DREAMMs Turn Fitful as FDA Questions Comeback in Multiple Myeloma
In advance of this week’s adcomm, the FDA flags ocular toxicities associated with the antibody-drug conjugate, which received accelerated approval in August 2020 but was pulled from the market two years later after a confirmatory trial failed to improve progression-free survival.
July 16, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Merck, AstraZeneca Cancer Collaborator Gets Swallowed Up by Sino Biopharm
Shanghai-based LaNova Medicines—which has captured the attention of some of the biggest Western pharmas—will be folded into fellow Chinese company Sino Biopharmaceutical in a deal worth up to $951 million.
July 16, 2025
·
1 min read
·
Tristan Manalac
Layoff Tracker
Ventus “Recalibrates” to Support Mid-Stage Trials
Follow along as
BioSpace
tracks job cuts and restructuring initiatives throughout 2025.
July 16, 2025
·
159 min read
·
BioSpace Editorial Staff
COVID-19
Vinay Prasad Overruled Reviewers on Moderna’s COVID-19 Shot for Kids
In a July 9 memo, the director of the FDA’s Center for Biologics Evaluation and Research contended there was not enough evidence that the benefits of Moderna’s COVID-19 vaccine Spikevax outweighed its risks in healthy children.
July 16, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025
July 16, 2025
·
1 min read
1 of 85,295
Next
